Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

1. A method of treating an airway disease in an equine, comprising administering to the equine a composition comprising a long-acting muscarinic antagonist (LAMA) or another pharmaceutically acceptable salt of the cation thereof.

2. The method according to claim 1 , wherein the LAMA is a compound of the general formula:

wherein

A denotes a double-bonded group selected from among

X— denotes an anion with a single negative charge,

R 1 and R 2 denote C 1 -C 4 -alkyl, which may optionally be substituted by hydroxy or halogen;

R 3 , R 4 , R 5 and R 6 , which may be identical or different, denote hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, hydroxy, CF3, CN, NO2 or halogen;

R7 denotes hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, C 1 -C 4 -alkylene-halogen, halogen-C 1 -C 4 -alkyloxy, C 1 -C 4 -alkylene-OH, CF3, —C 1 -C 4 -alkylene-C 1 -C 4 -alkyloxy, —O—COC 1 -C 4 -alkyl, —O—COC 1 -C 4 -alkyl-halogen, —O—COCF 3 or halogen,

optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, while

if A denotes

R 1 and R 2 denote methyl and

R 3 , R 4 , R 5 and R 6 denote hydrogen.

3. The method according to claim 2 , wherein the concentration of LAMA ranges between 0.2 to 7% m/V of the composition.

4. The method according to claim 2 , wherein the concentration of LAMA ranges between 0.3 to 6.0% m/V of the composition.

5. The method according to claim 2 , wherein the concentration of LAMA ranges between 0.4 to 5% m/V of the composition.

6. A method of administering a medicament to an animal, the method comprising administering to the animal a composition comprising a long-acting muscarinic antagonist (LAMA) or another pharmaceutically acceptable salt of the cation thereof in combination with a glucocorticoid.

7. The method according to claim 6 , wherein the animal is a mammal.

8. The method according to claim 7 , wherein the mammal is an equine.

9. The method according to claim 6 , wherein said glucocorticoid is ciclesonide or budesonide or a pharmaceutically acceptable salt thereof.

10. The method according to claim 9 , wherein said glucocorticoid is ciclesonide.

11. The method of claim 8 , wherein the method of administering further comprises a method for treating the equine for an airway disease.

12. The method according to claim 11 , wherein said glucocorticoid is ciclesonide, budesonide, or pharmaceutically acceptable salts thereof.

13. The method according to claim 11 , wherein said composition further comprises a beta-2 adrenoreceptor agonist.

14. The method according to claim 13 , wherein said beta-2 adrenoreceptor agonist is a long-acting beta-2 adrenergic agonist (LABA) or a pharmaceutically acceptable salt thereof.

15. The method according to claim 11 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient.

16. The method according to claim 11 , wherein the LAMA is a compound of the general formula:

wherein

A denotes a double-bonded group selected from among

X— denotes an anion with a single negative charge,

R 1 and R 2 denote C 1 -C 4 -alkyl, which may optionally be substituted by hydroxy or halogen;

R 3 , R 4 , R 5 and R 6 , which may be identical or different, denote hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, hydroxy, CF3, CN, NO2 or halogen;

R7 denotes hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, C 1 -C 4 -alkylene-halogen, halogen-C 1 -C 4 -alkyloxy, C 1 -C 4 -alkylene-OH, CF3, —C 1 -C 4 - alkylene-C 1 -C 4 -alkyloxy, —O—COC 1 -C 4 -alkyl, —O—COC 1 -C 4 -alkyl-halogen, —O—-COCF 3 or halogen,

optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof, while

if A denotes

R 1 and R 2 denote methyl and

R 3 , R 4 , R 5 and R 6 denote hydrogen.

17. The method according to claim 16 , wherein the airway disease is a pulmonary disease, preferably the airway disease is selected from the group consisting of: recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

18. The method according to claim 17 , wherein said LAMA or the composition comprising the LAMA is in a liquid formulation.

19. The method according to claim 18 , wherein said liquid formulation is a partially ethanolic formulation.

20. The method according to claim 18 , wherein said liquid formulation is for inhalation.

21. The method according to claim 1 , wherein said LAMA or the pharmaceutical composition comprising the LAMA is administered via an inhaler device comprising:

a. a pressurized metered dose inhaler or an aqueous/ ethanolic droplet inhaler; and

b. an adapter for equine use.

22. The method according to claim 21 , wherein said LAMAor the pharmaceutical composition comprising the LAMA is administered as an aerosol via the inhaler device.

23. The method according to claim 21 , wherein said LAMA or a pharmaceutically acceptable salt of the cation thereof is administered at a dose of 100 μg to 3000 μg ex inhaler.

24. The method according to claim 21 , wherein said dose is 200 μg to 2000 μg ex inhaler.

25. The method according to claim 21 , wherein said dose is 200 μg to 800 μg ex inhaler.

26. The method according to claim 21 , wherein ciclesonide or a pharmaceutically acceptable salt thereof is administered at a dose of 100 μg to 5000 μg ex inhaler.

27. The method according to claim 21 , wherein the dose is 450 μg to 3712.5 μg ex inhaler.

28. The method according to claim 21 , wherein the dose is 900 μg to 3712.5 μg ex inhaler.

29. The method according to claim 1 , wherein said composition is administered once or twice a day.

30. The method according to claim 1 , wherein the LAMA is a compound of the formula (LAMA 1):

31. The method according to claim 11 , wherein the LAMA is a compound of the formula (LAMA 1):